How immature T cells choose to become CD4 helper or CD8 killer cells
Signals that Control Thymocyte Migration
Looks at how signals in the thymus help immature T cells decide to become CD4 helper or CD8 killer cells, which affects how well people fight infections and build immunity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-11139617 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are using a detailed single-cell map of developing T cells to find the molecular signals that steer immature T cells into either CD4 helper or CD8 killer roles. They will track which signaling pathways activate the specific gene networks that define the CD4 fate and compare cells that recognize MHC class II versus MHC class I. The work uses laboratory experiments with cells and model systems to test how those signaling routes connect to the gene programs. This is basic science aimed at explaining how parts of the immune system are built rather than a trial offering treatment now.
Who could benefit from this research
Good fit: This project does not appear to recruit patients, though people with immune system development disorders or those interested in foundational immunology would be most likely to benefit from future applications.
Not a fit: People seeking immediate clinical treatment or enrolled in active therapeutic trials are unlikely to receive direct benefit from this basic laboratory research.
Why it matters
Potential benefit: If successful, this work could clarify how T cell types are specified and eventually guide better vaccines, immunotherapies, or treatments for immune development disorders.
How similar studies have performed: Previous single-cell and animal studies have mapped T cell development, but directly linking TCR signaling pathways to the CD4-versus-CD8 gene programs remains largely unresolved.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Robey, Ellen a — University of California Berkeley
- Study coordinator: Robey, Ellen a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.